The U.S. Food and Drug Administration approved the first facility in the United States to manufacture seasonal influenza vaccine using cell-based technology, according to the HHS.
That facility is located in Holly Springs, N.C., and is owned by Novartis of Basel, Switzerland. It can now manufacture cell-based vaccine against seasonal as well as pandemic influenza viruses.
With the approval of manufacturing in the Holly Springs facility, the capacity for seasonal influenza vaccine production in the United States can increase by at least 50 million doses.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough